Local News

• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Phase III begins for GAMMAGARD LIQUID plus rHuPH20 in primary immunodeficiency patients  Baxter International and Halozyme Therapeutics announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme for the treatment of primary immunodeficiency (PID).
  Halozyme Therapeutics, Inc. January 05, 2009  
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  
• GTx submits New Drug Application for toremifene 80 mg for the prevention of bone fractures  GTx announced the submission of a New Drug Application with the U.S. Food and Drug Administration (FDA) for toremifene 80 mg, an oral selective estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT).
  GTx, Inc. December 30, 2008  
• BLA for PolyHeme(R) accepted for filing and granted Priority Review  Northfield Laboratories announced that the FDA has accepted for filing its Biologics License Application (BLA) for PolyHeme(R), the Company's investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss.
  Northfield Laboratories, Inc. December 30, 2008  
• Stereotaxis to raise $20M in registered direct offering of common stock and warrants  Stereotaxis announced it has entered into definitive agreements with new and existing institutional investors to raise gross proceeds of $20 million through the sale of common stock and warrants in two separate concurrent transactions.
  Stereotaxis, Inc. December 29, 2008  
• Celera and Abbott revise strategic alliance  Celera and Abbott announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera.
  Celera Corporation December 29, 2008  
• Johnson & Johnson completes tender offer for Omrix Biopharmaceuticals  Johnson & Johnson announced that stockholders of Omrix Biopharmaceuticals tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock.
  Johnson & Johnson December 27, 2008  

   (next 10 articles)